<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Granisetron</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00889</strong>&#160; (APRD01002)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00889/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00889/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00889.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00889.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00889.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00889.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00889.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00889">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Granisetronum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Granisetron Hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000485/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000485/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: QYZRTBKYBJRGJB-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 348.171689149</li>
              <li>Average Mass: 348.87</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000485">DBSALT000485</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Granisol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Kytril</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Sancuso</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/serotonin-antagonists">Serotonin Antagonists</a></li>
<li><a href="/mesh/antiemetics">Antiemetics</a></li></ul></td></tr><tr><th>CAS number</th><td>109889-09-0</td></tr><tr><th>Weight</th><td>Average: 312.4094<br>Monoisotopic: 312.19501141</td></tr><tr><th>Chemical Formula</th><td>C<sub>18</sub>H<sub>24</sub>N<sub>4</sub>O</td></tr><tr><th>InChI Key</th><td>MFWNKCLOYSRHCJ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-methyl-N-{9-methyl-9-azabicyclo[3.3.1]nonan-3-yl}-1H-indazole-3-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN1N=C(C(=O)NC2CC3CCCC(C2)N3C)C2=CC=CC=C12</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzopyrazoles</td></tr><tr><th>Subclass</th><td>Indazoles</td></tr><tr><th>Direct parent</th><td>Indazoles</td></tr><tr><th>Alternative parents</th><td>Aminopiperidines; Benzene and Substituted Derivatives; Pyrazoles; Tertiary Amines; Secondary Carboxylic Acid Amides; Carboxylic Acids; Enolates; Polyamines</td></tr><tr><th>Substituents</th><td>4-aminopiperidine; piperidine; benzene; pyrazole; azole; tertiary amine; secondary carboxylic acid amide; carboxamide group; carboxylic acid derivative; enolate; polyamine; carboxylic acid; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the indazoles. These are compounds containing an indazole, which is structurally characterized by a pyrazole fused to a benzene.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).</td></tr><tr><th>Pharmacodynamics</th><td>Granisetron is a selective inhibitor of type 3 serotonergic (5-HT<sub>3</sub>) receptors. Granisetron has little or no affinity for other serotonin receptors, including 5-HT 1 , 5-HT 1A , 5-HT 1B/C , or 5-HT 2 ; for alpha 1 -, alpha 2 -, or beta-adrenoreceptors; for dopamine D 2 receptors; for histamine H 1 receptors; for benzodiazepine receptors; for picrotoxin receptors; or for opioid receptors. In most human studies, granisetron has had little effect on blood pressure, heart rate, or electrocardiogram (ECG). The drug is structurally and pharmacologically related to ondansetron, another selective inhibitor of 5-HT<sub>3</sub> receptors. The serontonin 5-HT<sub>3</sub> receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting.</td></tr><tr><th>Mechanism of action</th><td>Granisetron is a potent, selective antagonist of 5-HT<sub>3</sub> receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.</td></tr><tr><th>Absorption</th><td>Absorption of is rapid and complete, though oral bioavailability is reduced to about 60% as a result of first pass metabolism.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>65%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Primarily hepatic; undergoes N -demethylation and aromatic ring oxidation followed by conjugation. Animal studies suggest that some of the metabolites may have 5-HT 3 receptor antagonist activity.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Granisetron</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li></ul></td><td><a href="/metabolites/DBMET00406">9'-desmethylgranisetron</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/409">Details</a></td></tr><tr><td>Granisetron</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li></ul></td><td><a href="/metabolites/DBMET00407">7-hydroxygranisetron</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/410">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>The remainder of the dose is excreted as metabolites, 48% in the urine and 38% in the feces.</td></tr><tr><th>Half life</th><td>4-6 hours in healthy patients, 9-12 hours in cancer patients</td></tr><tr><th>Clearance</th><td><ul>
	<li>0.52 L/h/kg [Cancer Patients with 1 mg bid for 7 days]</li>
	<li>0.41 L/h/kg [Healthy subject with a single 1 mg dose]</li>
</ul></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>&gt;2000 mg/kg (rat, oral)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9947</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9515</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5231</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5473</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.6287</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.7243</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5895</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6978</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8546</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9019</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8841</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9073</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8355</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.6016</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5878
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8464
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9868
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.3943 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9083
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.5458
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Strakan international ltd</li>
<li>Akorn inc</li>
<li>App pharmaceuticals llc</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Bedford laboratories</li>
<li>Claris lifesciences ltd</li>
<li>Dr reddys laboratories inc</li>
<li>Ebewe pharma</li>
<li>Sagent strides llc</li>
<li>Sandoz canada inc</li>
<li>Teva parenteral medicines inc</li>
<li>Watson laboratories inc</li>
<li>Wockhardt usa inc</li>
<li>App pharmaceuticals</li>
<li>Hikma farmaceutica (portugal) sa</li>
<li>Hoffmann la roche inc</li>
<li>Cypress pharmaceutical inc</li>
<li>Apotex inc</li>
<li>Barr laboratories inc</li>
<li>Cipla ltd</li>
<li>Corepharma llc</li>
<li>Dr reddys laboratories ltd</li>
<li>Mylan pharmaceuticals inc</li>
<li>Natco pharma ltd</li>
<li>Orchid healthcare</li>
<li>Roxane laboratories inc</li>
<li>Taro pharmaceuticals usa inc</li>
<li>Teva pharmaceuticals usa</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.amerigenpharma.com">Amerigen Pharmaceuticals Inc.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://www.ascendlaboratories.com">Ascend Laboratories LLC</a></li>
<li><a href="http://www.avevadds.com">Aveva Drug Delivery Systems Inc.</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.cipla.com">Cipla Ltd.</a></li>
<li><a href="http://www.corepharma.com">Corepharma LLC</a></li>
<li><a href="http://www.curapharma.com">Cura Pharmaceutical Co. Inc.</a></li>
<li><a href="http://www.davapharma.com">DAVA Pharmaceuticals</a></li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li><a href="http://www.ebewe.at">Ebewe Pharma</a></li>
<li><a href="http://www.roche.com">F Hoffmann La Roche Ltd.</a></li>
<li><a href="http://www.roche.com">F Hoffmann-La Roche Ltd.</a></li>
<li><a href="http://www.gsk.com">GlaxoSmithKline Inc.</a></li>
<li><a href="http://www.hawthornrx.com">Hawthorn Pharmaceuticals</a></li>
<li><a href="http://www.hikma.com">Hikma Pharmaceuticals</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neuman Distributors Inc.</li>
<li>Northstar Rx LLC</li>
<li><a href="http://www.orchidpharma.com">Orchid Healthcare</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prostrakan.com">Prostrakan Inc.</a></li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intravenous</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Sancuso 3.1 mg/24 hr patch</td><td>372.0USD</td><td>patch</td></tr><tr><td>Kytril 2 1 mg tablet Box</td><td>131.98USD</td><td>box</td></tr><tr><td>Kytril 1 mg tablet</td><td>62.94USD</td><td>tablet</td></tr><tr><td>Granisetron hcl 1 mg tablet</td><td>60.19USD</td><td>tablet</td></tr><tr><td>Granisetron hcl 4 mg/4 ml vial</td><td>24.0USD</td><td>ml</td></tr><tr><td>Kytril 1 mg Tablet</td><td>20.27USD</td><td>tablet</td></tr><tr><td>Apo-Granisetron 1 mg Tablet</td><td>14.14USD</td><td>tablet</td></tr><tr><td>Kytril 0.1 mg/ml vial</td><td>11.54USD</td><td>ml</td></tr><tr><td>Granisetron hcl 0.1 mg/ml vial</td><td>7.2USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>7608282</td><td>2004-10-22</td><td>2024-10-22</td></tr><tr><td>United States</td><td>5952340</td><td>1996-09-14</td><td>2016-09-14</td></tr><tr><td>Canada</td><td>2158354</td><td>2004-07-13</td><td>2014-03-15</td></tr><tr><td>Canada</td><td>2100777</td><td>2003-08-19</td><td>2012-01-16</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>219 &#176;C (HCl salt)</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>2.6</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>4.34e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.64</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.88</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-2.9</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>14.75</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>9</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>50.16</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>101.83</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>35.39</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Neal Ward, David Alan Jones, Victor Witold Jacewicz, &#8220;Process for the preparation of granisetron.&#8221; U.S. Patent US6268498, issued April, 1986.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=6268498&amp;tbm=pts" target="_blank">US6268498 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li><a href="http://www.medsafe.govt.nz/Profs/Datasheet/k/Kytriltabinj.htm">Link</a></li>
	<li>Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? <span class="caps">CNS</span> Drugs. 2005;19(3):225-38. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15740177">Pubmed</a></li>
	<li>Tan M: Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2003 Sep;4(9):1563-71. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12943486">Pubmed</a></li>
	<li>Feyer P, Seegenschmiedt MH, Steingraeber M: Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies. Support Care Cancer. 2005 Sep;13(9):671-8. Epub 2005 Jul 26. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16044252">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D04370" target="_blank">D04370 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07023" target="_blank">C07023 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3510" target="_blank">3510 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505137" target="_blank">46505137 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.3390.html" target="_blank">3390 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50000483" target="_blank">50000483 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000295" target="_blank">DAP000295 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA449809" target="_blank">PA449809 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=2300" target="_blank">2300 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2300" target="_blank">2300 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2088371" target="_blank">2088371 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/granisetron.htm" target="_blank">http://www.rxlist.com/cgi/generic/granisetron.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/granisetron.html" target="_blank">http://www.drugs.com/cdi/granisetron.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Granisetron" target="_blank">Granisetron <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>A04AA02<ul class="atc-drug-tree"><li><a href="/atc/A#A">A &#8212; ALIMENTARY TRACT AND METABOLISM</a></li><li><a href="/atc/A04#A04">A04 &#8212; ANTIEMETICS AND ANTINAUSEANTS</a></li><li><a href="/atc/A04A#A04A">A04A &#8212; ANTIEMETICS AND ANTINAUSEANTS</a></li><li><a href="/atc/A04AA#A04AA">A04AA &#8212; Serotonin (5HT3) antagonists</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>56:22.20</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00889.pdf?1265922807">show</a>(77.3 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00889.pdf?1265922745">show</a>(51.7 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>